LifeSci Capital analyst Rami Katkhuda has maintained their neutral stance on AKRO stock, giving a Hold rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Rami Katkhuda has given his Hold rating due to a combination of factors surrounding Akero Therapeutics’ recent acquisition by Novo Nordisk. The acquisition deal, valued at up to $5.2 billion, includes an upfront payment and a contingent value right (CVR) based on the regulatory approval of efruxifermin in cirrhotic MASH by mid-2031. This transaction offers a significant premium over Akero’s recent stock prices, reflecting a strategic move by Novo Nordisk to strengthen its position in the FGF21 analog space.
Despite the promising acquisition terms, the Hold rating reflects the inherent uncertainties tied to the regulatory approval process and the competitive landscape in the FGF21 market. Akero’s ongoing Phase III SYNCHRONY program, which aims to secure full approval across various stages of MASH, is a critical factor in determining the future success of the acquisition. The market’s response, coupled with Akero’s current cash burn rate and short interest, suggests a cautious approach until more definitive outcomes from the clinical trials and regulatory reviews are available.
Katkhuda covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, MoonLake Immunotherapeutics, and Mineralys Therapeutics, Inc.. According to TipRanks, Katkhuda has an average return of 27.5% and a 52.74% success rate on recommended stocks.
In another report released today, Canaccord Genuity also downgraded the stock to a Hold with a $54.00 price target.